40 completed, 5 unknown, 4 active not recruiting, 4 recruiting. 33 Phase 3, 12 Phase 2, 12 Phase 4, 6 Phase 1.
Follow Chickenpox Vaccine: new trials by email Literature Review of Chickenpox Vaccine trials Research Report on Chickenpox Vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years NBP608 (Mid Potency), NBP608 (Low Potency), Varivax® - Varicella (Chickenpox) | Phase 3 | Recruiting | SK Bioscience Co., Ltd. | 780 | 2026-07-04 | 2026-09-15 |
| Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Varicella Vaccine - Varicella (Chickenpox), Varicella Immunisation | Phase 3 | Not yet recruiting | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 300 | 2026-06-15 | 2026-06-12 |
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age MMRVNS, MMRV - Measles, Measles-Mumps-Rubella+Chickenpox Vaccine | Phase 3 | Recruiting | GlaxoSmithKline | 1209 | 2026-05-11 | 2026-07-08 |
| A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years MG1111 (Barycela inj.), VARIVAX™ - Varicella (Chickenpox), Chickenpox Vaccine | Phase 3 | Recruiting | GC Biopharma Corp | 474 | 2026-03-17 | 2026-04-17 |
| Correlation of Protection Against Varicella in an Exploratory Study Varicella vaccine - Varicella | Not yet recruiting | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 400 | 2025-10-10 | 2025-01-27 | |
| Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age PCV21 vaccine, Vaxneuvance vaccine, Hexyon vaccine - Pneumococcal Immunization, Healthy Volunteers | Phase 3 | Active not recruiting | Sanofi | 1092 | 2025-05-22 | 2026-03-02 |
| Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine Vaicella Vaccine+DTaP on Day 0, MMR on Day 30, Varicella vaccine+MMR on Day 0，DTaP on Day 30, Varicella Vaccine - Varicella (chickenpox), MMR Vaccine | Phase 4 | Not yet recruiting | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 720 | 2025-05-01 | 2025-03-24 |
| Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine - Pneumococcal Immunization | Phase 3 | Active not recruiting | Sanofi | 580 | 2025-02-27 | 2026-02-13 |
| Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine - Pneumococcal Immunization | Phase 3 | Active not recruiting | Sanofi | 2360 | 2025-02-18 | 2026-04-13 |
| Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine - Pneumococcal Immunization | Phase 3 | Active not recruiting | Sanofi Pasteur, a Sanofi Company | 1714 | 2024-12-18 | 2026-04-22 |
| Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion) Varicella vaccine+TIV, Varicella vaccine, TIV - Varicella, Influenza Vaccine | Phase 4 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 899 | 2024-09-21 | 2025-05-23 |
| Study on Booster Immunization With Varicella Vaccine at Different Intervals Varicella vaccine - VZV, Varicella Immunisation | Phase 4 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 412 | 2024-09-21 | 2025-05-29 |
| Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine - RSV Immunization | Phase 3 | Terminated | Sanofi Pasteur, a Sanofi Company | 2226 | 2024-05-13 | 2026-10-05 |
| Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines Varicella Vaccine, Varivax - Varicella | Phase 3 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 642 | 2024-02-29 | 2025-01-27 |
| Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination MG1111 (BARICELA), VARIVAX, Suduvax - Varicella | Phase 2 | Recruiting | Green Cross Corporation | 230 | 2022-07-05 | 2024-01-24 |
| Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine Varicella vaccine - Persistence of Varicella Immunity | Phase 4 | Withdrawn | University of Colorado, Denver | 2021-12-01 | 2021-02-09 | |
| Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon rVSVΔG-ZEBOV-GP, V920, Fibre and equilibrate breakfast and lunch, Active detection and treatment of pathogens - Ebola Virus Disease | Phase 1 / Phase 2 | Completed | Centre de Recherche Médicale de Lambaréné | 120 | 2021-04-09 | 2023-04-20 |
| Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3 - Pneumococcal Immunisation, Diphtheria Immunisation | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 852 | 2020-05-22 | 2025-09-08 |
| Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) V114, Prevenar 13™, Vaxelis™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1191 | 2019-08-28 | 2023-05-06 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) V114, Prevnar 13™, RotaTeq™ - Pneumococcal Infections, Pneumococcal Vaccines | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1720 | 2019-06-19 | 2023-07-28 |
Showing 20 of 62. Sign in to see all of them.
Chickenpox (28) · Measles (11) · Mumps (9) · Rubella (9) · Meningococcal Infections (6) · Meningitis (4) · Haemophilus Infections (3) · Hepatitis A (3) · Influenza, Human (3) · Meningitis, Meningococcal (3) · Pneumococcal Infections (3) · Asthma (1) · Dengue (1) · Diphtheria (1) · Encephalitis, Japanese (1)
GlaxoSmithKline (11) · Merck Sharp & Dohme LLC (9) · Sanofi Pasteur, a Sanofi Company (7) · Sinovac (Dalian) Vaccine Technology Co., Ltd. (6) · Green Cross Corporation (3) · Sanofi (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · SK Bioscience Co., Ltd. (2) · SK Chemicals Co., Ltd. (2) · University of Colorado, Denver (2) · AstraZeneca (1) · Beijing Center for Disease Control and Prevention (1) · Butantan Institute (1) · Centre de Recherche Médicale de Lambaréné (1) · GC Biopharma Corp (1)
United States (26) · Puerto Rico (13) · Thailand (9) · Philippines (7) · China (6) · Mexico (6) · Finland (5) · Honduras (5) · South Korea (5) · Turkey (Türkiye) (4) · Australia (3) · Czechia (3) · Estonia (3) · Italy (3) · Spain (3)
Amir Tejani, MD (1) · Amy Feldman, MD (1) · Bertill Andersson (1) · Beverly L. Connelly, MD (1) · Expedito J Luna, MD (1) · Glacus S Brito, MD (1) · Hee-jin Cheong (1) · Jeffrey Venstrom, MD (1) · Kelly MacDonald, MD (1)
PMID 22327493, PMID 19305145, PMID 19366435, PMID 21813857, PMID 22094635, PMID 23744509, PMID 27879555, PMID 28481690, PMID 28939581, PMID 29325161, PMID 29800309, PMID 30325891, PMID 30511963, PMID 31282539, PMID 31306399, PMID 31725115, PMID 32307279, PMID 34473594, PMID 34702124, PMID 35083365, PMID 35144847, PMID 36522265, PMID 36621410, PMID 36841723, PMID 37846456, PMID 38637212, PMID 40833801, PMID 41337697
2018 (4), 2016 (1), 2019 (1), 2023 (1), 2025 (1)